February 1, 1998Human & Experimental Toxicology

Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymerdoxorubicin (PK1)

View Full Paper

Ask AI

Bookmark

Population

MF1 mice and Wistar rats

Design

Preclinical

Follow-up

Up to 59 days

Authors

RDRuth DuncanGoethe University Frankfurt JCJ K Coatsworth SBS S BurtlesQueen Mary University of London

Discussion

Member takes

Implication

Supports Phase I progression; leaves open human translation of rat toxicities.

Structured PICO

Population

MF1 mice and Wistar rats

Intervention

HPMA copolymer-doxorubicin (PK1) administered i.v. as single doses (22.5 or 45 mg/kg) or multiple weekly doses for 5 weeks (12.0 or 22.5 mg/kg in mice; 3 and 5 mg/kg in rats)

Outcome

Toxicity including mortality, haematological changes, clinical chemistry, and histological changes at necropsysafety

Preclinical toxicology of the novel polymeric anticancer agent PK1 established its safety profile and a recommended starting dose of 20 mg/m2 for Phase I clinical trials.

Cite This Study

Duncan et al. (1998) studied this question.

synapsesocial.com/papers/6a02ef6e59ea043e4c9e36eb https://doi.org/10.1177/096032719801700204

View Full Paper

Ask AI

Bookmark

Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymerdoxorubicin (PK1)

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymerdoxorubicin (PK1)

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider